$743.35
arrow_drop_down0.21%Is REGN a Buy or Sell based on AI Analysis?
Fundamental Analysis
Regeneron Pharmaceuticals Inc (REGN) has a strong balance sheet with a current ratio of 5.69, indicating the company's ability to cover its short-term liabilities with its current assets. Furthermore, the company has a quick ratio of 4.94, highlighting its strong liquidity position. Additionally, Regeneron has a low debt-to-equity ratio of 0.1, indicating prudent financial management and lower financial risk. The company's return on equity of 16.26% reflects its ability to generate profit from shareholder equity, showcasing its efficiency in utilizing investor funds. Moreover, the company's gross margin of 93.26% indicates strong profitability and efficient cost management in its operations. Regeneron Pharmaceuticals Inc also demonstrates strong revenue growth, with a revenue growth rate of 7.76%. The company's net margin of 30.14% reflects its ability to convert revenue into profit efficiently. Furthermore, Regeneron's price-to-sales ratio of 8.22 suggests that the stock may be undervalued relative to its revenue, making it an attractive investment opportunity. Additionally, the company has a solid operating margin of 29.2%, indicating efficient cost management and operational efficiency. With a market cap of $104.79B and a strong market growth score of 69, Regeneron Pharmaceuticals Inc is positioned well for future growth and profitability in the healthcare sector.
Positive Development
Regeneron Pharmaceuticals Inc. has been outperforming its competitors in the market, indicating strong performance and investor confidence. The company's stock has been rising steadily, indicating a positive trend in the market. The company's stock has been underperforming on some days, but it has consistently shown resilience and bounced back quickly.
Negative Development
Regeneron's stock has been experiencing fluctuations in price, which could be a cause for concern for investors. The company's stock has underperformed on certain days, which may indicate a lack of investor confidence or a market downturn. Regeneron's stock has a relatively high PE ratio of 24.2025, indicating that it may be overvalued and could experience a correction in the future.
Technical Analysis
Regeneron Pharmaceuticals Inc (REGN) currently has a technical rating of "SELL" based on various indicators such as MACD, ADX, and ROC. The stock price has seen a decline of 1.23% with a delta price of -$12.04. The seven-day price change percent is -0.78%, indicating a recent downward trend in the stock price. The company's stock sector in healthcare has shown a positive change of 28.95% over the past year, outperforming the market benchmark of 18.53% in analyst forecast price change percent. The company has 107.94 million shares outstanding and has a market cap of $104.79 billion. In terms of technical indicators, the company has one buy indicator (ATR), three hold indicators (MACD, ADX, and ROC), and four sell indicators (RSI, CCI, WILLR, and STOCHRSI) for the month. The technical analysis suggests that the stock may be experiencing a bearish trend in the short term. Additionally, the company's beta is low at 0.11, indicating lower volatility compared to the overall market. The stock's trailing PE ratio is 28.25 and the price to book ratio is 4.15, which are important metrics for evaluating the stock's valuation. Overall, the technical analysis points towards cautiousness for investors considering Regeneron Pharmaceuticals Inc.
Conclusion and recommendation
Based on the data provided, it is recommended to hold onto the stock of Regeneron Pharmaceuticals Inc (REGN). The company has a strong market position with a market capitalization of $104.79 billion and a solid financial performance, as evidenced by its revenue of $13.12 billion and net income of $3.95 billion. Regeneron also has robust return metrics, with a return on assets of 8.49% and a return on equity of 16.26%. Additionally, the company has shown consistent growth in its revenue, with a 7.76% revenue growth rate and a five-year price change percent of 123.77%. While the stock may have experienced a slight decrease in price recently, it is important to consider the long-term growth potential and stability of the company. In conclusion, Regeneron Pharmaceuticals Inc presents a promising investment opportunity for those looking for a stable and profitable company in the healthcare sector. With a solid financial foundation, consistent revenue growth, and strong market position, Regeneron is well-positioned for future success. While short-term fluctuations in the stock price may occur, investors can feel confident in holding onto their investment in Regeneron for long-term growth and value appreciation. It is advisable to monitor the company's performance and market conditions closely to make informed decisions about buying, holding, or selling the stock.